Related Experiment Video
Updated: Dec 6, 2025
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Profiling Anti-Apoptotic BCL-xL Protein Expression in Glioblastoma Tumorspheres
Deborah Fanfone1,2,3, Ahmed Idbaih4,5, Jade Mammi1,2,3
1Cancer Research Centre of Lyon (CRCL) INSERM 1052, CNRS 5286, 69008 Lyon, France.
Abstract:
Glioblastoma (GBM) is one of the cancers with the worst prognosis, despite huge efforts to understand its unusual heterogeneity and aggressiveness. This is mainly due to glioblastoma stem cells (GSCs), which are also responsible for the frequent tumor recurrence following surgery, chemotherapy or radiotherapy. In this study, we investigate the expression pattern of the anti-apoptotic BCL-xL protein in several GBM cell lines and the role it might play in GSC-enriched tumorspheres. We report that several GBM cell lines have an increased BCL-xL expression in tumorspheres compared to differentiated cells. Moreover, by artificially modulating BCL-xL expression, we unravel a correlation between BCL-xL and tumorsphere size. In addition, BCL-xL upregulation appears to sensitize GBM tumorspheres to newly developed BH3 mimetics, opening promising therapeutic perspectives for treating GBM patients.
Insights
Glioblastoma stem cells (GSCs) show increased BCL-xL protein expression, correlating with tumorsphere size. Upregulating BCL-xL sensitizes these GSCs to BH3 mimetics, offering new glioblastoma treatment strategies.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Glioblastoma (GBM) presents a poor prognosis due to its heterogeneity and aggressiveness.
- Glioblastoma stem cells (GSCs) drive tumor recurrence after standard treatments.
- Understanding GSC biology is crucial for developing effective GBM therapies.
Purpose of the Study:
- To investigate the expression of the anti-apoptotic BCL-xL protein in GBM cell lines.
- To determine the role of BCL-xL in GSC-enriched tumorspheres.
- To explore therapeutic potential of targeting BCL-xL in GBM.
Main Methods:
- Analysis of BCL-xL expression in GBM cell lines and tumorspheres.
- Artificial modulation of BCL-xL expression.
- Assessment of tumorsphere size and sensitivity to BH3 mimetics.
Main Results:
- Increased BCL-xL expression was observed in GSC-enriched tumorspheres compared to differentiated cells.
- BCL-xL expression levels correlated with tumorsphere size.
- Upregulation of BCL-xL sensitized GBM tumorspheres to BH3 mimetics.
Conclusions:
- BCL-xL plays a significant role in GSC-enriched GBM tumorspheres.
- Targeting BCL-xL may represent a promising therapeutic strategy for GBM.
- BH3 mimetics show potential for treating GBM patients by targeting BCL-xL.
